Antimicrobial resistance (AMR) poses a serious threat to modern medicine and may render
common infections untreatable. The discovery of new antibiotics has come to a relative standstill during the last decade [1], and developing novel approaches to tackle the spread of AMR
genes will require significant efforts in the coming years ...
Antimicrobial resistance (AMR) poses a serious threat to modern medicine and may render
common infections untreatable. The discovery of new antibiotics has come to a relative standstill during the last decade [1], and developing novel approaches to tackle the spread of AMR
genes will require significant efforts in the coming years [2]. In 2014, several groups independently demonstrated how CRISPR-Cas (clustered regularly interspaced short palindromic
repeats-CRISPR–associated), a bacterial immune system now widely used for genome editing,
can selectively remove AMR genes from bacterial populations. Here, we discuss the current
state of the field of CRISPR-Cas antimicrobials, the challenges ahead, and how they may be
overcome.
